Last update :
19/11/2024
References   References 3604  
Type : Manufacturer

Research teams :
Authors :
Title : Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Reference : Sanofi Aventis France 2012

Level of Evidence : 
Manufacturer's stability data
Physical stability : 
Chemical stability : 
Other methods : 
Comments : 

List of drugs
injectionDaunorubicin hydrochloride Anticancer drug
Incompatible + injectionDexamethasone sodium phosphate
Incompatible + injectionFludarabine phosphate
Incompatible + injectionHeparin sodium
Incompatible + injectionHydrocortisone sodium succinate
Incompatible + injectionMethylprednisolone acetate
Incompatible + injectionMethylprednisolone sodium succinate
injectionDexamethasone sodium phosphate Anti-inflammatory
Incompatible + injectionDaunorubicin hydrochloride
injectionFludarabine phosphate Anticancer drug
Incompatible + injectionDaunorubicin hydrochloride
injectionHeparin sodium Anticoagulant
Incompatible + injectionDaunorubicin hydrochloride
injectionHydrocortisone sodium succinate Anti-inflammatory
Incompatible + injectionDaunorubicin hydrochloride
injectionMethylprednisolone acetate Anti-inflammatory
Incompatible + injectionDaunorubicin hydrochloride
injectionMethylprednisolone sodium succinate Anti-inflammatory
Incompatible + injectionDaunorubicin hydrochloride

  Mentions Légales